Improving perioperative outcomes in patients with end-stage heart failure

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Nussmeier, Nancy A ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Cardiac surgery; Heart failure; Heart assist device; Transplantation

Indexed keywords

ANTICOAGULANT AGENT; BENZAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENOLDOPAM; GLYCERYL TRINITRATE; INOTROPIC AGENT; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ARTICLE; ASSISTED CIRCULATION; CARDIOPULMONARY HEMODYNAMICS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DILATATION; DISEASE SEVERITY; DRUG SELECTIVITY; EXPERIENCE; HEART ASSIST DEVICE; HEART FAILURE; HEART OUTPUT; HEART TRANSPLANTATION; HEART VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG BLOOD VESSEL; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MESENTERY BLOOD VESSEL; MULTIPLE ORGAN FAILURE; ORGAN DONOR; PATIENT CARE; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; TECHNOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; VASODILATATION;

CARDIAC SURGICAL PROCEDURES; DOPAMINE AGONISTS; FENOLDOPAM; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; TREATMENT OUTCOME;

EID: 0037245089     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Givertz MM, Wilson SC, Braunwald E. Clinical aspects of heart failure: high-output failure; pulmonary edema. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a Textbook of Cardiovascular Medicine. 6th ed. Philadelphia, Pa: WB Saunders; 2001:534-561.
2. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001.
3. Argenziano M, Goldstein DJ, Oz MC, Rose EA. Cardiac transplantation for end-stage heart disease. Cardiol Rev. 1999;7:349-355.
4. Barnard CN. The operation. A human cardiac transplant: an interim report for a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967;41:1271-1274.
5. Cooley DA, Bloodwell RD, Hallman GL, Nora JJ. Transplantation of the human heart: report of four cases. JAMA. 1968;205:479-486.
6. Hosenpud JD, Bennett LE, Keck BM, et al: The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant. 2000;19:909-931.
7. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. New Engl J Med. 1998;339:1522-1533.
8. Cooley DA, Liotta D, Hallman GL, et al. Orthotopic cardiac prosthesis for two-staged cardiac replacement. Am J Cardiol. 1969;24:723-730.
9. Norman JC, Brook MI, Cooley DA, et al. Total support of the circulation of a patient with post-cardiotomy stone-heart syndrome by partial artificial heart (ALVAD) for 5 days followed by heart and kidney transplantation. Lancet. 1978;1:1125-1127.
10. Cooley DA, Akutsu T, Norman JC, et al. Total artificial heart in two staged cardiac transplantation. Cardiovasc Dis Bull Tex Heart Inst. 1981;8:305-319.
11. Starnes VA, Oyer PE, Fortner P, et al. Isolated left ventricular assist as bridge to cardiac transplantation. J Thorac Cardiovasc Surg. 1988;96:62-71.
12. Dowling RD, Etoch SW. Clinically available extracorporeal assist devices. Prog Cardiovasc Dis. 2000;43:27-36.
13. Mets B. Anesthesia for left ventricular assist device placement. J Cardiothorac Vasc Anesth. 2000;14:316-326.
14. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
15. Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg. 1999;68:734-741.
16. Rose EA, Frazier OH. Resurrection after mechanical circulatory support. Circulation. 1997;96:393-395.
17. Westaby S, Katsumata T, Houel R, et al. Jarvik 2000 heart: potential for bridge to myocyte recovery. Circulation. 1998;98:1568-1574.
18. Levin HR, Oz MC, Chen JM, et al. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation. 1995;91:2717-2720.
19. Muller J, Wallukat G, Weng YG, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation. 1997;96:542-549.
20. Bick RJ, Poindexter B, Buja LM, et al. Alterations in cardiomyocytes following left ventricular unloading. Recent Res Dev Membr Biol. In press.
21. Rother A, Collard CD. Anesthetic management for cardiac transplantation. In: Hensley FA, Martin DE, eds. A Practical Approach to Cardiac Anesthesia. 3rd ed. Boston: Little, Brown and Company; 2002: In press.
22. Potluri S, Uber P, Mehra M. Difficult cases in heart failure: expanding the therapeutic armamentarium in decompensated heart failure: using intravenous fenoldopam. Congest Heart Fail. 2001;7:51-52.
23. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant. 1995;14:436-443.
24. Kirklin JK, Naftel DC, Kirklin JW, et al. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant. 1988;7:331-336.
25. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
26. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548-1557.
27. Young JB, Leon CA, Pratt CM, et al. Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside. Am Heart J. 1988;115:378-384.
28. Thielmeier KA, Pank JR, Dowling RD, Gray LA. Anesthetic and perioperative considerations in patients undergoing placement of totally implantable replacement hearts. Sem Cardiothorac Vasc Anesth. 2001;5:335-344.
29. Frishman WH, Hotchkiss H. Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatment. Am Heart J. 1996; 132:861-870.
30. Kim MO, Koh PO, Kim JH, et al. Localization of dopamine D1 and D2 receptor mRNAs in the rat systemic and pulmonary vasculatures. Mol Cells. 1999;9:417-421.
31. Ventura HO, Messerli FJ, Frohlich ED, et al. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation. 1984;69:1142-1145.
32. Oparil S, Aronson S, Deeb GM, et al. Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens. 1999;12:653-664.
33. Ozono R, O'Connell DP, Wang ZQ, et al. Localization of the dopamine D1 receptor protein in the human heart and kidney. Hypertension. 1997;30(3 pt 2):725-729.
34. Halpenny M, Lakshmi S, O'Donnell A, et al. The effects of fenoldopam on coronary conduit blood flow after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2001;15:72-76.
35. Barnard ML, Ridge KM, Saldias F, et al. Stimulation of the dopamine 1 receptor increases lung edema clearance. Am J Respir Crit Care Med. 1999;160:982-986.
36. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med. 1999;27:1832-1837.
37. Denton M, Chertow G, Brady H. Dopamine and acute renal failure. Kidney Int. 1996;49:4-14.
38. Thompson B, Cockrill B. Renal-dose dopamine: a siren song? Lancet. 1994;344:7-8.
39. Kien ND, Moore PG, Jaffe KS. Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. Anesth Analg. 1992;74:72-78.
40. Carey RM, Siragy HM Ragsdale NV, et al. Dopamine-1 and dopamine-2 mechanisms in the control of renal function. Am J Hypertens. 1990;3(6 pt 2):59S-63S.
41. Murphy MB, McCoy CE, Weber RR, et al. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine 1 agonist fenoldopam. Circulation. 1987;76:1312-1318.
42. White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med. 1989;149:870-874.
43. Gold J, Cullinane S, Chen J, et al. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Cardiol. 2000;85:506-508.
44. Morales DLS, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg. 2000,69:102-106.